Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 633

1.

Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms.

Rose JE, Behm FM, Ramsey C, Ritchie JC Jr.

Nicotine Tob Res. 2001 Nov;3(4):383-90.

PMID:
11694206
2.

Precessation treatment with nicotine skin patch facilitates smoking cessation.

Rose JE, Behm FM, Westman EC, Kukovich P.

Nicotine Tob Res. 2006 Feb;8(1):89-101.

PMID:
16497603
3.

Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment.

Rose JE, Herskovic JE, Behm FM, Westman EC.

Nicotine Tob Res. 2009 Sep;11(9):1067-75. doi: 10.1093/ntr/ntp103. Epub 2009 Jun 30.

PMID:
19567826
4.

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.

Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV.

Clin Pharmacol Ther. 1994 Jul;56(1):86-99.

PMID:
8033499
5.

Treating smokers before the quit date: can nicotine patches and denicotinized cigarettes reduce cravings?

Rezaishiraz H, Hyland A, Mahoney MC, O'Connor RJ, Cummings KM.

Nicotine Tob Res. 2007 Nov;9(11):1139-46.

PMID:
17978987
6.

Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments.

Rose JE, Behm FM.

Nicotine Tob Res. 2004 Jun;6(3):523-32.

PMID:
15203786
7.

Mecamylamine does not precipitate withdrawal in cigarette smokers.

Eissenberg T, Griffiths RR, Stitzer ML.

Psychopharmacology (Berl). 1996 Oct;127(4):328-36.

PMID:
8923568
8.

Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking.

Rose JE, Behm FM, Westman EC.

Pharmacol Biochem Behav. 2001 Feb;68(2):187-97.

PMID:
11267622
9.

New medications for nicotine dependence treatment.

Hurt RD.

Nicotine Tob Res. 1999;1 Suppl 2:S175-9; discussion S207-10. Review.

PMID:
11768177
11.
12.

A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers.

Berlin I, Saïd S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, Lecrubier Y, Puech AJ.

Clin Pharmacol Ther. 1995 Oct;58(4):444-52.

PMID:
7586937
13.

Relationships between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B: activity, affinity labeling, and protein measurements.

Snell LD, Glanz J, Tabakoff B; WHO/ISBRA Study on State and Trait Markers ofAlcohol Use and Dependence Investigators.

Alcohol Clin Exp Res. 2002 Jul;26(7):1105-13.

PMID:
12170121
14.

Nicotine patch therapy in adolescent smokers.

Smith TA, House RF Jr, Croghan IT, Gauvin TR, Colligan RC, Offord KP, Gomez-Dahl LC, Hurt RD.

Pediatrics. 1996 Oct;98(4 Pt 1):659-67.

PMID:
8885942
15.

Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence.

Gilbert DG, Zuo Y, Browning RA, Shaw TM, Rabinovich NE, Gilbert-Johnson AM, Plath L.

Nicotine Tob Res. 2003 Dec;5(6):813-9.

PMID:
14668065
16.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
17.

Increase in anger symptoms after smoking cessation predicts relapse.

Patterson F, Kerrin K, Wileyto EP, Lerman C.

Drug Alcohol Depend. 2008 May 1;95(1-2):173-6. doi: 10.1016/j.drugalcdep.2008.01.013. Epub 2008 Mar 6.

PMID:
18328642
18.

Nicotine dependence, withdrawal symptoms, and adolescents' readiness to quit smoking.

Prokhorov AV, Hudmon KS, de Moor CA, Kelder SH, Conroy JL, Ordway N.

Nicotine Tob Res. 2001 May;3(2):151-5.

PMID:
11403729
19.

Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia.

Weinberger AH, Sacco KA, Creeden CL, Vessicchio JC, Jatlow PI, George TP.

Schizophr Res. 2007 Mar;91(1-3):217-25. Epub 2007 Feb 9.

20.

Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.

Rose JE, Behm FM, Westman EC.

Exp Clin Psychopharmacol. 1998 Aug;6(3):331-43.

PMID:
9725117

Supplemental Content

Support Center